High-Dose Influenza Vaccine and Hospitalization Risk in Older Adults

Seasonal influenza creates outsized risk for older adults. Beyond fever and cough, influenza often triggers pneumonia, cardiac stress, metabolic instability, and prolonged recovery. These downstream effects explain why hospitalization, not infection alone, defines the true clinical burden in this age group.

Immune responses also change with age. Antibody production weakens, memory responses fade, and vaccine effectiveness declines. This process, often called immunosenescence, shapes how preventive strategies should evolve after age 65.

A large 2025 New England Journal of Medicine trial, known as GALFLU, addressed this issue directly. The study examined whether a high-dose inactivated influenza vaccine could reduce serious clinical outcomes, especially hospitalizations, compared with the standard-dose vaccine.

Why vaccine dose matters after age 65

Standard influenza vaccines reduce infection risk across populations. However, their effectiveness often drops to 30–50% in older adults, particularly for severe disease. Protection against hospitalization may fall even further.

The high-dose inactivated influenza vaccine was developed to address this gap. It contains four times more hemagglutinin antigen per strain than the standard dose, 60 mcg versus 15 mcg per strain. This higher antigen exposure aims to produce a stronger and more durable immune response.

Earlier trials confirmed improved protection against laboratory-confirmed influenza. Until recently, data linking high-dose vaccination to fewer hospitalizations remained limited, which made GALFLU particularly important.

How the GALFLU trial was designed

GALFLU was a pragmatic, registry-based, randomized trial conducted in Galicia, Spain. Investigators enrolled community-dwelling adults aged 65 to 79 during two influenza seasons, 2023–2024 and 2024–2025.

Participants received either a high-dose or standard-dose quadrivalent inactivated influenza vaccine. Randomization occurred at existing regional vaccination sites, which mirrored routine clinical care and minimized participant burden.

The primary outcome focused on hospitalization for influenza or pneumonia. Events counted only after 14 days post-vaccination and continued through the end of the influenza season. This outcome choice emphasized meaningful clinical consequences rather than laboratory markers alone.

Who participated in the study

The trial randomized more than 103,000 unique participants. Over 31,000 individuals enrolled in both seasons and were counted separately for each season’s analysis.

Participants averaged just over 72 years of age, and about 54% were men. Chronic conditions were common, including hypertension, cardiovascular disease, and prior cancer. This profile closely resembles real-world older adult populations seen in everyday practice.

Individuals aged 80 and older and nursing home residents were excluded, since those groups already routinely receive high-dose vaccination in that region.

What the study found

Across both influenza seasons, hospitalization rates remained low in absolute terms. However, consistent differences emerged between vaccine groups.

Hospitalization for influenza or pneumonia occurred less often in the high-dose group. Hospitalizations specifically attributed to influenza also favored the high-dose vaccine. Smaller protective trends appeared for cardiorespiratory hospitalizations, all-cause hospitalizations, and all-cause mortality.

These results are summarized below.

Key Outcomes From the GALFLU Trial

Outcome	High-Dose Vaccine	Standard-Dose Vaccine	Relative Vaccine Effectiveness
Hospitalization for influenza or pneumonia	0.26%	0.34%	24%
Hospitalization for influenza	0.09%	0.14%	32%
Hospitalization for pneumonia	0.17%	0.21%	16%
Cardiorespiratory hospitalization	1.47%	1.60%	8%
Hospitalization for any cause	6.46%	6.63%	3%
Death from any cause	0.45%	0.52%	13%

Serious adverse events occurred at similar rates in both groups. Vaccine-related serious reactions were rare, and no deaths were attributed to vaccination.

How to interpret these numbers thoughtfully

At first glance, absolute differences such as 0.26% versus 0.34% may appear small. However, hospitalization represents a major inflection point in older adult health.

Hospital stays often trigger muscle loss, delirium, medication changes, and loss of independence. Even a modest reduction in admission risk can meaningfully alter long-term trajectories.

From a population perspective, these differences compound across tens of thousands of older adults each season. They also reduce pressure on hospitals during winter surges, when capacity becomes strained.

The table below helps place relative and absolute risk into practical context.

Understanding Relative and Absolute Risk Together

Perspective	What the numbers show	Why it matters
Absolute risk	Hospitalizations remain uncommon overall	Severe events still drive decline
Relative reduction	Roughly 20–30% fewer flu-related admissions	Targets outcomes patients fear most
Population effect	Small differences multiply at scale	Health system impact grows
Safety profile	Serious adverse events appear similar	Benefit does not trade off safety
Functional impact	Fewer admissions reduce deconditioning	Independence lasts longer

Why hospitalization prevention matters beyond infection

Influenza acts as a systemic stressor. It raises inflammatory signaling, increases insulin resistance, and strains the cardiovascular system. For patients with diabetes, glucose variability often worsens rapidly during infection. For those with heart disease, clotting risk and fluid shifts increase.

Vaccination therefore functions as a systems-level intervention. It helps stabilize multiple physiologic domains at once, not just respiratory symptoms.

The GALFLU findings align with prior observational studies and pooled randomized data from other European trials. Together, this evidence supports high-dose vaccination as part of a broader, thoughtful preventive strategy for older adults.

Patient cases from an integrated care perspective

• Diabetes with winter instability: A 70 year old man experiences glucose spikes during infections. High-dose vaccination helps him avoid hospitalization and maintain metabolic control.
• Heart failure with prior flu admissions: A 75 year old woman previously required hospitalization after influenza-related fluid overload. High-dose vaccination reduces her recurrence risk.
• Chronic lung disease: A 68 year old former smoker with COPD often develops pneumonia after viral illness. High-dose vaccination lowers his admission risk during peak season.
• Post-cancer frailty: A 73 year old man recovering from chemotherapy prioritizes avoiding hospitalization during immune recovery. High-dose vaccination supports that goal.
• Active older adult with frequent travel: A 66 year old woman travels often and values preserving independence. High-dose vaccination reduces her risk of winter disruption.

Practical takeaway

The GALFLU trial suggests that high-dose inactivated influenza vaccine reduces hospitalizations for influenza or pneumonia in adults aged 65 to 79, without increasing serious adverse events. While absolute risks remain low, the relative reductions carry meaningful clinical and system-level implications.

At our practice in Montgomery County, Maryland, and through virtual care, we help patients integrate vaccination choices into a personalized, holistic strategy that supports immune resilience, metabolic stability, cardiovascular health, and long-term independence.